USE OF BIOMARKERS IN DIAGNOSING AND TREATING LUPUS NEPHRITIS
The present disclosure relates to methods of diagnosing lupus nephritis or proliferative lupus nephritis in a subject, methods of predicting a subject's risk of developing lupus nephritis and methods of determine whether a subject suffering from lupus nephritis is responding to treatment. The methods herein involve detecting the presence of or level of at least one biomarker which is IL-16, Galectin-1, CD163, CD206, FOLR2, proteinase 3, or a combination thereof.
1 . A method of diagnosing lupus nephritis in a subject, the method comprising the steps of:
(a) obtaining a biological sample from a subject;
(b) detecting a presence of at least one biomarker in the sample, wherein at least one of the biomarkers is IL-16, Galectin-1, CD163, CD206, FOLR2, proteinase 3 (PRTN3), or a combination thereof; and
(c) diagnosing the subject as having lupus nephritis if at least one of IL-16, Galectin-1, CD163, CD 206, FOLR2, or PRTN3 is detected in the sample.
2 . The method of claim 1 , wherein the biomarkers IL-16, Galectin-1, CD163, CD206, FOLR2 and PRTN3 are detected in the sample from the subject.
3 . The method of claim 1 or claim 2 , wherein the method further comprises detecting the presence of at least one additional biomarker in the sample, wherein the biomarker is from Table 1.
4 . The method of any of claims 1-3 , wherein presence of at least one biomarker in the sample is displayed on an instrument.
5 . The method of any of claims 1-4 , wherein the method further comprises treating the subject diagnosed with lupus nephritis with at least one immunosuppressant, at least one corticosteroid, at least one B-lymphocyte stimulator specific inhibitor, rituximab, or any combination thereof.
6 . The method of any of claims 1-5 , wherein the sample is a whole blood, serum, plasma, or urine.
7 . A method of predicting a subject's risk of developing lupus nephritis, the method comprising the steps of:
(a) obtaining a biological sample from a subject;
(b) determining a level of at least one biomarker in the sample, wherein at least one of the biomarkers is IL-16, Galectin-1, CD163, CD206, FOLR2, proteinase 3 (PRTN3), or a combination thereof;
(c) comparing the level of the at least one biomarker determined in step (b) with a control level for the same biomarker; and
(d) predicting whether the subject at risk of developing lupus nephritis based on the comparison in step (c).
8 . The method of claim 7 , wherein the level of IL-16, Galectin-1, CD163, CD206, FOLR2, and PRTN3 are determined in the sample from the subject.
9 . The method of claim 7 or claim 8 , wherein the method further comprises determining the level of at least one additional biomarker in the sample, wherein the biomarker is from Table 1.
10 . The method of any of any of claims 7-9 , wherein the method further comprises determining that the subject is at risk of developing lupus nephritis when the level of the at least one biomarker determined in step (b) is higher than the control level or that the subject is not at risk of developing lupus nephritis when the level of the at least one biomarker determined in step (b) is lower than the control level.
11 . The method of claim 10 , wherein the method further comprises treating the patient for lupus nephritis if the subject is determined to be at risk of developing lupus nephritis.
12 . The method of claim 11 , wherein the subject is treated with at least one immunosuppressant, at least on corticosteroid, a B-lymphocyte stimulator specific inhibitor, rituximab, or a combination thereof.
13 . The method of claim 12 , wherein the at least one immunosuppressant is cyclosporine, tacrolimus, a calcineurin-inhibitor, cyclophosphamide, hydroxychloroquine, azathioprine, mycophenolate, or any combination thereof.
14 . The method of any of claim 12 or claim 13 , wherein the corticosteroid is prednisone, prednisolone, methylprednisolone, or any combination thereof.
15 . The method of any of claims 7-14 , wherein concentration of at least one biomarker in the sample is displayed on an instrument.
16 . The method of claims 7-15 , wherein the sample is a whole blood, serum, plasma, or urine.
17 . A method of determining whether a subject suffering from lupus nephritis is responding to treatment, the method comprising the steps of:
(a) obtaining a biological sample from a subject being treated for lupus nephritis;
(b) determining a level at least one biomarker in the sample, wherein at least one of the biomarkers are IL-16, Galectin-1, CD163, CD206, FOLR2, proteinase 3 (PRTN3), or a combination thereof;
(c) comparing the level of the at least one biomarker determined in step (b) with a control level for the same biomarker; and
(d) determining that the subject is responding to treatment for lupus nephritis if the level of the at least one biomarker determined in step (b) is less than the control level for the same biomarker or that the subject is not responding to treatment for lupus nephritis if the level of the at least one biomarker determine in step (b) is the same as or greater than the control level for the same biomarker.
18 . The method of claim 17 , wherein the control level for a biomarker is the level of the biomarker obtained from the subject prior to the start of treatment.
19 . The method of claim 17 or claim 18 , wherein the level of IL-16, Galectin-1, CD163, CD206, FOLR2, and PRTN3 are determined in the sample from the subject.
20 . The method of claim 19 , wherein the sample is obtained from the subject after 3 months of treatment.
21 . The method of any of claims 17-20 , wherein the method further comprises determining the level of at least one additional biomarker in the sample, wherein the biomarker is from Table 1.
22 . The method of any of claims 17-21 , wherein the method comprises monitoring the subject receiving treatment for the lupus nephritis.
23 . The method of any of claims 17-22 , wherein subject is treated with at least one immunosuppressant, at least on corticosteroid, a B-lymphocyte stimulator specific inhibitor, rituximab, or a combination thereof.
24 . The method of claim 23 , wherein the at least one immunosuppressant is cyclosporine, tacrolimus, a calcineurin-inhibitor, cyclophosphamide, hydroxychloroquine, azathioprine, mycophenolate, or any combination thereof.
25 . The method of any of claim 23 or claim 24 , wherein the corticosteroid is prednisone, prednisolone, methylprednisolone, or any combination thereof.
26 . The method of any of claims 17-25 , wherein the level of at least one biomarker in the sample is displayed on an instrument.
27 . The method of claims 17-26 , wherein the sample is a whole blood, serum, plasma, or urine.
28 . The method of any of claims 1-27 , wherein the lupus nephritis is proliferative lupus nephritis.
29 . A method for determining a type or grade of lupus nephritis in a subject, the method comprising the steps of:
(a) obtaining a biological sample from a subject being treated for lupus nephritis;
(b) determining a level at least one biomarker in the sample, wherein at least one of the biomarkers are IL-16, CD163, Catalase, PRTN3, S100A8, Azurocidin, and MMP8, or a combination thereof; and
(c) determining that the type or grade of the lupus nephritis is proliferative when the level of the at least one biomarker determined in step (b) is higher than the control level for the same biomarker or that the type or grade of the lupus nephritis is pure membranous when the level of the at least one biomarker determined in step (b) is less than the control level for the same biomarker.
30 . An article of manufacture comprising a set of reagents to measure the levels of a panel of biomarkers in a biological sample, wherein the panel of biomarkers comprises IL-16, Galectin-1, CD163, CD206, FOLR2, and proteinase 3 (PRTN3) and optionally, at least one biomarker in Table 1, and wherein the set of reagents are bound to a solid support and specifically binds to the biomarkers.
31 . The article of manufacture of claim 30 , wherein the reagents are specific binding partners.
32 . The article of manufacture of claim 31 , wherein the specific binding partner is an antibody or antigen-binding fragment thereof. a peptide or a fragment thereof, or a combination thereof.
33 . The article of manufacture of any of claims 30-32 , wherein the solid support is a biochip, a microtiter plate, a stick, a bead or any combination thereof.
34 . A test kit comprising the set of reagents of claim 30 .